MedTrace Logo

Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute

NCT00841152 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-03-16

No results posted yet for this study

Summary

This study is designed to perform a head-to-head comparison of two synthetic ceramic bone graft substitutes, bioactive glass (BAG) and beta-tricalcium phosphate (TCP), in filling of contained bone defects following surgical evacuation of benign bone tumor or tumor-like conditions. Based on the investigators' previous preclinical research and an ongoing single-center randomized clinical trial on bioactive glass filling, the investigators expect BAG filling to be more efficient compared to TCP in promotion of defect healing and functional recovery after surgery.

Conditions

  • Bone Neoplasm

Interventions

DEVICE

Bioactive glass

Surgical implantation

DEVICE

Beta-tricalcium phosphate (ChronOs)

Surgical implantation

PROCEDURE

Autograft

Surgical transplantation from iliac crest

PROCEDURE

Allograft (frozen femoral head)

Surgical transplantation

Sponsors & Collaborators

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Hannu T Aro, MD, PhD · Turku University Central Hospital and University of Turku

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-02-28
Completion
2018-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841152 on ClinicalTrials.gov